IPR decision: Oct. 05, 2020
|
AIA Review # |
Filing Date |
Institution Date |
Petitioner |
Patent |
Respondent |
Final Written
Decision |
|
IPR2016-01479 |
07/22/2016 |
02/15/2017 |
Par Pharmaceutical,
Inc*. |
9,006,224 |
Novartis AG |
Challenged claims patentable |
*This proceeding as
initially filed named Par Pharmaceutical, Inc. as the sole Petitioner. Argentum
Pharmaceutical LLC was joined as a party to this proceeding via a Motion for
Joinder in IPR2017-01063; West-Ward Pharmaceuticals International Limited was joined
as a party via a Motion for Joinder in IPR2017-01078. Subsequently, Par and
West-Ward separately requested termination of their participation in the
proceeding pursuant to settlement. Argentum Pharmaceutical LLC is the sole
remaining Petitioner.
US 9,006,224 (Novartis AG; Exp: 07/01/2028)
1. A method for treating pancreatic neuroendocrine tumors,
comprising administering to a human subject in need thereof a therapeutically
effective amount of 40-O-(2-hydroxyethyl)-rapamycin as a monotherapy and wherein
the tumors are advanced tumors after failure of cytotoxic chemotherapy.
No comments:
Post a Comment